Synapse - Saad Usmani

Results (345)

High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors

Meeting Abstract

Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
Blood (2024)

Fulltext@MSK | Save

Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma

Meeting Abstract

Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
Blood (2024)

Fulltext@MSK | Save

Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
Blood (2024)

Fulltext@MSK | Save

Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response

Meeting Abstract

Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
Blood (2024)

Fulltext@MSK | Save

Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma

Meeting Abstract

Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Idecabtagene vicleucel (Ide-cel) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up

Meeting Abstract

Paul, B.; Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
Blood (2024)

Fulltext@MSK | Save

Feasibility and implementation of the ASH Research Collaborative's COVID-19 OutcomeS in Myeloma and the Impact of VaCcines (COSMIC): A decentralized, real-world evidence study for patients with multiple myeloma to monitor outcomes related to COVID-19 vaccines and infections

Meeting Abstract

Wood, W. A.; Semmel, E. A.; James, S.; Neuberg, D. S.; Hewitt, K.; Anderson, K. C.; Kumar, S.; Schroeder, M. A.; Chung, D. J.; Rosenberg, A. S.; more...
Blood (2024)

Fulltext@MSK | Save

Patient-centered care in hematology: How side effect severity influences decision-making autonomy in relapsed refractory multiple myeloma

Meeting Abstract

Martinez, J. A. H.; Quiroz, F. F.; Ahlstrom, J. M.; Fonseca, R.; Strain, J. R.; Iadeluca, L.; Jensen, R. M.; Chmielewski, C.; Usmani, S. Z.; Hydren, J. R.
Blood (2024)

Fulltext@MSK | Save

Radiation therapy for oligo-relapsed/progressive disease post-stem cell transplant for multiple myeloma: Factors associated with favorable outcomes